Recombinant Human CA8 protein

**Background of CA8 Recombinant Protein**

Carbonic anhydrase VIII (CA8), a member of the carbonic anhydrase (CA) family, is a unique isoform distinguished by its lack of enzymatic activity due to the absence of critical histidine residues required for catalytic function. Unlike other CAs, which regulate pH and CO₂ metabolism, CA8 is thought to act as a regulatory or structural protein. It is primarily expressed in the cerebellum and has been implicated in neuronal development, synaptic signaling, and calcium homeostasis.

The CA8 gene, located on chromosome 8 in humans, encodes a 28 kDa protein that shares homology with other CA family members but retains distinct structural features. Studies link CA8 mutations or dysregulation to neurological disorders such as cerebellar ataxia, autism spectrum disorders, and intellectual disabilities, highlighting its role in maintaining cerebellar integrity.

Recombinant CA8 protein is produced via genetic engineering, typically using bacterial (e.g., *E. coli*) or mammalian expression systems. This involves cloning the CA8 gene into an expression vector, followed by transfection, protein purification (e.g., affinity chromatography), and validation (e.g., Western blot, mass spectrometry). Recombinant CA8 enables functional studies, including its interaction with inositol 1.4.5-trisphosphate receptors (IP3Rs) in calcium signaling pathways, and its potential as a therapeutic target or biomarker.

Research on recombinant CA8 has advanced understanding of its non-enzymatic roles in neurobiology and disease mechanisms, offering insights for diagnostic or therapeutic strategies in cerebellar pathologies. Its production continues to support structural analyses and drug discovery efforts targeting CA8-associated disorders.